Cochlear Stock

Cochlear EBIT CAGR 10Y

The EBIT CAGR (10 Year) of Cochlear (COH.AX) as of Aug 24, 2026 is 9.28 %. In the previous year, EBIT CAGR (10 Year) was 9.28 % — a change of 0.00% (lower).

EBIT CAGR 10Y

9.28 %

YoY

0.00%

Last updated:

EBIT CAGR (10 Year) of Cochlear is 2026 9.28 % . EBIT CAGR (10 Year) of Cochlear was 2025 9.28 % . It decreases by 0.00% lower compared to the previous year.

The Cochlear EBIT CAGR 10Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 10Y
Date
EBIT CAGR 10Y
Jan 1, 2018
9.28 AUD
Jan 1, 2019
9.28 AUD
Jan 1, 2020
9.28 AUD
Jan 1, 2021
9.28 AUD
Jan 1, 2022
9.28 AUD
Jan 1, 2023
9.28 AUD
Jan 1, 2024
9.28 AUD
Jan 1, 2025
9.28 AUD
The Cochlear EBIT CAGR 10Y history
YEAREBIT CAGR 10YYoY
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %0.00%
9.28 %—
Access this data via the Eulerpool API
Get Free API Key

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

EBIT CAGR (10 Year) of Cochlear is 9.28 % in 2026.

On Eulerpool you can find the complete historical development of EBIT CAGR (10 Year) Cochlear since 2006 – with annual values, charts, and detailed analysis.

The 10-year EBIT CAGR shows the long-term compound annual growth rate of operating earnings.

To evaluate EBIT CAGR (10 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (10 Year).

EBIT CAGR (10 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (10 Year)'s Cochlear historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — Cochlear

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Cochlear